Show simple item record

dc.contributor.authorFurst, Daniel E.
dc.contributor.authorKay, Jonathan
dc.contributor.authorWasko, Mary Chester
dc.contributor.authorKeystone, Edward
dc.contributor.authorKavanaugh, Arthur
dc.contributor.authorDeodhar, Atul
dc.contributor.authorMurphy, Frederick T.
dc.contributor.authorMagnus, Jeanette H.
dc.contributor.authorHsia, Elizabeth C.
dc.contributor.authorHsu, Benjamin
dc.contributor.authorXu, Stephen
dc.contributor.authorRahman, Mahboob U.
dc.contributor.authorDoyle, Mittie K.
dc.date2022-08-11T08:10:51.000
dc.date.accessioned2022-08-23T17:22:16Z
dc.date.available2022-08-23T17:22:16Z
dc.date.issued2013-10-01
dc.date.submitted2015-04-17
dc.identifier.citationFurst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013 Oct;52(10):1845-55. doi: 10.1093/rheumatology/ket233. Epub 2013 Jul 9. PubMed PMID: 23838027; PubMed Central PMCID: PMC3775295. <a href="http://dx.doi.org/10.1093/rheumatology/ket233">Link to article on publisher's site</a>
dc.identifier.issn1462-0324 (Linking)
dc.identifier.doi10.1093/rheumatology/ket233
dc.identifier.pmid23838027
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48708
dc.description.abstractOBJECTIVE: To evaluate the effect of golimumab on haemoglobin levels in patients with RA, PsA or AS. METHODS: Secondary analysis was performed on integrated data from five randomized controlled studies: three RA, one PsA and one AS (2303 patients total). Golimumab 50 or 100 mg was injected s.c. every 4 weeks with or without MTX. Control groups received placebo injections plus MTX or background therapy. Patients with haemoglobin levels below the age- and sex-specific normal ranges were considered to have anaemia. Ferritin levels were used to distinguish anaemia of mixed aetiology ( > /= 15 and < 60 ng/ml) and anaemia of inflammation ( > /= 60 ng/ml). Changes from baseline to weeks 14 and 24 in haemoglobin level were compared between treatment groups using an analysis of variance on the van der Waerden normal scores. RESULTS: At baseline, 21% of RA patients, 9% of PsA patients and 15% of AS patients had anaemia. Of these, 24%, 57% and 25%, respectively, had anaemia of inflammation. The median increase from baseline to week 14 in the haemoglobin level of anaemic patients was 0.3 g/dl in the control group and 0.9 g/dl in the golimumab group (P < 0.001). Haemoglobin levels improved within the subgroups of patients with anaemia of mixed aetiology (control, 0.4 g/dl vs golimumab, 0.7 g/dl) (P = 0.305) and with anaemia of inflammation (0.2 vs 1.4 g/dl, respectively) (P < 0.001). CONCLUSION: Compared with the control group, patients receiving golimumab treatment had significantly improved haemoglobin levels, particularly among patients with anaemia of inflammation.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23838027&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775295/
dc.subjectAdult
dc.subjectAnemia
dc.subjectAntibodies, Monoclonal
dc.subjectAntirheumatic Agents
dc.subjectArthritis
dc.subjectArthritis, Psoriatic
dc.subjectArthritis, Rheumatoid
dc.subjectC-Reactive Protein
dc.subjectDose-Response Relationship, Drug
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectHemoglobins
dc.subjectHumans
dc.subjectInflammation Mediators
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectRandomized Controlled Trials as Topic
dc.subjectSpondylitis, Ankylosing
dc.subjectTumor Necrosis Factor-alpha
dc.subjectMusculoskeletal Diseases
dc.subjectRheumatology
dc.subjectSkin and Connective Tissue Diseases
dc.titleThe effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
dc.typeJournal Article
dc.source.journaltitleRheumatology (Oxford, England)
dc.source.volume52
dc.source.issue10
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/rheumatology_pubs/104
dc.identifier.contextkey7002930
html.description.abstract<p>OBJECTIVE: To evaluate the effect of golimumab on haemoglobin levels in patients with RA, PsA or AS.</p> <p>METHODS: Secondary analysis was performed on integrated data from five randomized controlled studies: three RA, one PsA and one AS (2303 patients total). Golimumab 50 or 100 mg was injected s.c. every 4 weeks with or without MTX. Control groups received placebo injections plus MTX or background therapy. Patients with haemoglobin levels below the age- and sex-specific normal ranges were considered to have anaemia. Ferritin levels were used to distinguish anaemia of mixed aetiology ( > /= 15 and < 60 ng/ml) and anaemia of inflammation ( > /= 60 ng/ml). Changes from baseline to weeks 14 and 24 in haemoglobin level were compared between treatment groups using an analysis of variance on the van der Waerden normal scores.</p> <p>RESULTS: At baseline, 21% of RA patients, 9% of PsA patients and 15% of AS patients had anaemia. Of these, 24%, 57% and 25%, respectively, had anaemia of inflammation. The median increase from baseline to week 14 in the haemoglobin level of anaemic patients was 0.3 g/dl in the control group and 0.9 g/dl in the golimumab group (P < 0.001). Haemoglobin levels improved within the subgroups of patients with anaemia of mixed aetiology (control, 0.4 g/dl vs golimumab, 0.7 g/dl) (P = 0.305) and with anaemia of inflammation (0.2 vs 1.4 g/dl, respectively) (P < 0.001).</p> <p>CONCLUSION: Compared with the control group, patients receiving golimumab treatment had significantly improved haemoglobin levels, particularly among patients with anaemia of inflammation.</p>
dc.identifier.submissionpathrheumatology_pubs/104
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.source.pages1845-55


This item appears in the following Collection(s)

Show simple item record